Arcus Biosciences, Inc. (RCUS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150M 300M 450M Q3 '21: 9.5M Q4 '21: 354.6M Q1 '22: 18M Q2 '22: 27M Q3 '22: 33M Q4 '22: 34M Q1 '23: 25M Q2 '23: 29M Q3 '23: 32M Q4 '23: 31M Q1 '24: 145M Q2 '24: 39M Q3 '24: 48M Q4 '24: 26M Q1 '25: 28M Q2 '25: 160M Q3 '25: 26M Q4 '25: 33M Q1 '26: 17M Q2 '26: 41M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-200M -100M 0 100M 200M 300M Q3 '21: -78.1M Q4 '21: 281M Q1 '22: -67M Q2 '22: -69M Q3 '22: -70M Q4 '22: -74M Q1 '23: -86M Q2 '23: -83M Q3 '23: -80M Q4 '23: -91M Q1 '24: -16M Q2 '24: -106M Q3 '24: -105M Q4 '24: -103M Q1 '25: -122M Q2 '25: -8M Q3 '25: -142M Q4 '25: -114M Q1 '26: -134M Q2 '26: -96M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-200M -100M 0 100M 200M 300M Q3 '21: -78M Q4 '21: 279.5M Q1 '22: -68M Q2 '22: -67M Q3 '22: -65M Q4 '22: -67M Q1 '23: -80M Q2 '23: -75M Q3 '23: -71M Q4 '23: -81M Q1 '24: -4M Q2 '24: -93M Q3 '24: -92M Q4 '24: -94M Q1 '25: -112M Q2 '25: 0 Q3 '25: -135M Q4 '25: -106M Q1 '26: -128M Q2 '26: -91M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-250M 0 250M 500M 750M Q3 '21: -53.8M Q4 '21: -61.9M Q1 '22: 654M Q2 '22: -65M Q3 '22: -81M Q4 '22: -70M Q1 '23: -98M Q2 '23: -57M Q3 '23: -63M Q4 '23: -88M Q1 '24: -2M Q2 '24: -94M Q3 '24: 26M Q4 '24: -100M Q1 '25: -132M Q2 '25: -133M Q3 '25: -97M Q4 '25: -120M Q1 '26: -138M Q2 '26: -119M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-250M 0 250M 500M 750M Q3 '21: -61.6M Q4 '21: -70.4M Q1 '22: 651M Q2 '22: -66M Q3 '22: -83M Q4 '22: -70M Q1 '23: -101M Q2 '23: -62M Q3 '23: -73M Q4 '23: -94M Q1 '24: -6M Q2 '24: -94M Q3 '24: 25M Q4 '24: -101M Q1 '25: -133M Q2 '25: -133M Q3 '25: -97M Q4 '25: -121M Q1 '26: -138M Q2 '26: -119M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q3 '19: 43.9M Q1 '20: 44.3M Q2 '20: 48.6M Q3 '20: 65.1M Q4 '20: 63.5M Q3 '21: 70.1M Q1 '22: 71.2M Q2 '22: 71.8M Q3 '22: 72.2M Q1 '23: 73M Q2 '23: 73.2M Q3 '23: 74.6M Q1 '24: 86.2M Q2 '24: 91.1M Q3 '24: 91.4M Q1 '25: 98.4M Q2 '25: 106.5M Q3 '25: 106.5M Q1 '26: 125.4M Q2 '26: 126.1M Q1 '20 Q4 '20 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -4.15 Q4 '21: 0.71 Q1 '22: 0.83 Q2 '22: 0.99 Q3 '22: 1.20 Q4 '22: -3.72 Q1 '23: -3.85 Q2 '23: -3.96 Q3 '23: -4.00 Q4 '23: -4.15 Q1 '24: -3.11 Q2 '24: -3.09 Q3 '24: -3.15 Q4 '24: -3.10 Q1 '25: -4.19 Q2 '25: -3.17 Q3 '25: -3.44 Q4 '25: -3.31 Q1 '26: -3.19 Q2 '26: -3.91 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.